Navigation Links
Research Report on BioClinica, Inc. as Speculative Buy
Date:11/29/2009

ATLANTA, Nov. 29 /PRNewswire/ -- The following is an investment opinion release issued by Intellivest Securities Research, Inc.

Intellivest Securities Research, Inc., ("ISR") a Georgia registered investment advisor, has published a Report on BioClinica, Inc. ( BIOC) which serves companies in the pharmaceutical, biotechnology and medical device industries. A primary service is helping their clients manage, process and submit medical imaging portions of their submissions relating to their clinical trials to regulators, primarily the U.S. Food and Drug Administration and comparable European agencies, to evaluate product efficacy and safety. BioClinica has provided services to more than 130 firms in connection with over 2,000 clinical partners since its founding in 1990.

The Research Report rates BioClinica, Inc. as a Speculative Buy because the FDA and other regulators are encouraging more clinical trial data to be submitted in an electronic format. As an early mover in this area, BioClinica is well positioned to exploit this trend. BIOC has a strong balance sheet and an attractive valuation. It has no debt, adequate cash, growing positive cash flow and enjoys significant operating leverage. BioClinica's shares are currently trading around two times book value and one times revenue. It has an experienced, highly competent management team, who, along with Board members, own about 9% of outstanding shares. BIOC has worked with the world's leading bio-pharmaceutical companies including three that are Dow Jones Industrial Average components: Johnson & Johnson, Merck, and Pfizer.

BioClinica has recently completed the integration of its two most recent acquisitions both of which should be accretive in 2010. BIOC reported positive results for the third quarter ending 9/30.

The Report states that BioClinica faces a number of risks including the uncertainty facing the entire pharmaceutical industry as a result of proposed health reform legislation.

About the Report

Intellivest Securities Research, Inc.'s research is distributed by Intellivest Securities, Inc., (FINRA, SIPC, RIA, SIFMA), whose Office of Supervisory Jurisdiction is located at 1540 Chase Court, Riverdale, GA. 30296-2610. Please read the Research Report for certain disclaimers and disclosures. Daniel H. Kolber is the author of the Report and www.DowJonesMonitor.com, a daily blog that aggregates articles about the Dow Jones 30 components (not affiliated with Dow Jones). He holds these licenses: Series 24, 27, 87, 53, 4, 79, 65; is a member of the Georgia, New York, Florida and Virginia Bars, and has the B.A. from Boston University, the J.D. from University of Virginia School of Law and the Ll.M. from New York University School of Law.

Intellivest Securities Research, Inc.'s (CRD #147288) research is distributed as third party research by its affiliate, Intellivest Securities, Inc. (CRD #145022) which is a member of the Financial Industry Regulatory Authority,.

www.intellivestsecurities.com

SOURCE Intellivest Securities Research, Inc.


'/>"/>
SOURCE Intellivest Securities Research, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Research sheds light on workings of anti-cancer drug
2. Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental
3. MISSION Skincare(R) Supports GNCs Efforts To Raise Money for St. Jude Childrens Research Hospital(R)
4. Researchers identify proteins in lung cancer cells that may provide potential drug targets
5. Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research
6. Research Yields Clues to Severe Form of Sinusitis
7. AIDS research reveals a lack of family-planning programs in Uganda
8. Ann Taylor Stores Corp. Returns To St. Jude Childrens Research Hospitals Thanks and Giving Campaign(R) For The Third Year
9. New research shows versatility of amniotic fluid stem cells
10. Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
11. Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... planning assistance from offices in Pasco and Richland, is initiating a charity drive ... serious injuries resulting from a recent automobile collision. , On October 29th ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I have gout, and ... this old family recipe, which is meant to relieve gout and pain caused by ... a 12-hour energy boost every time. It relieved what VA doctors called the worst ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... proudly announced today that a new solution for Emergency Departments (ED) has been ... tight space in Emergency Department examination rooms, and with a simplified pallet of ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology: